Prevention and Management of Tuberculosis in Transplant Recipients: From Guidelines to Clinical Practice.
Transplant recipients are at increased risk for tuberculosis (TB), which can adversely affect graft viability and patient survival. Scientific societies and official organizations have therefore issued guidelines and consensus statements for TB prevention and treatment. However, due to the poor supporting evidence, the current recommendations largely rely on expert opinion rather than on properly designed studies. In this overview, we aim to gather together the previous experience and compare and contrast the main current guidelines on the prevention and treatment of TB in solid organ transplantation and hematopoietic stem cell transplantation.
1 Tuberculosis Unit, Service of Infectious Diseases, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. 2 Department of Clinical Sciences, University of Barcelona, L'Hospitalet de Llobregat, Barcelona, Spain.
Laura
L
Muñoz
Miguel
M
Santin
D000995:Antitubercular Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019317:Evidence-Based Medicine; D006085:Graft Survival; D019983:Guideline Adherence; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects* / Q000592:standards; D006801:Humans; D016867:Immunocompromised Host; D007166:Immunosuppressive Agents / Q000009:adverse effects; D009894:Opportunistic Infections / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control* / Q000635:transmission; D016377:Organ Transplantation / Q000009:adverse effects* / Q000592:standards; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D016896:Treatment Outcome; D014376:Tuberculosis / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control* / Q000635:transmission
D000995:Antitubercular Agents; D007166:Immunosuppressive Agents